ASeq Newsletter • 29 implied HN points • 06 Jan 26
- Illumina’s clinical business is strengthening while overall revenue is flat-to-down, and the company will likely report modest results without launching new sequencing instruments.
- Oxford Nanopore probably won’t surprise before the new CEO starts in March, since recent gains looked driven by financial restructuring and price increases rather than clear instrument growth.
- PacBio has made technical progress and landed some population sequencing wins, but recent quarterly declines and doubts about reaching profitability by 2027 make acquisition rumors understandable yet unlikely.